Clinical Trials

    Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/?HER2- Breast Cancer (ReDiscover-2)

    Investigator: Polly Niravath

    Study Coordinator: Alexys Brock

    Status: Enrolling

    ClinicalTrials.gov Number: NCT06982521

    Phone: 346.238.4814

    Protocol Number: PRO00041722

    Description


    This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment with a CDK4/6 inhibitor.